
Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …

Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run clinical trials of Adaptimmune’s potential …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

